Study | Year | Country | Time period of patient inclusion | No. of participants (C/U) | No. of kneesa (C/U) | Mean age (range, years) | Mean follow-up time (years) | Main outcomesb |
---|---|---|---|---|---|---|---|---|
Parker | 2001 | Canada | 1987.1–1988.12 | 48/52 | 31/36 | 66.7 (50.6–76) | 12.8 | 1 |
Baker | 2007 | UK | 1987.6–1997.2 | 219/177 | 151/118 | 70.5 (41–88) | 8.8 | 1 |
Park | 2011 | Korea | 1997.1–1998.2 | 53/53 | 50/50 | 58.4 (51–67) | 13.6 | 1, 2, 3, 4, 5, 7, 8 |
Pijls | 2012 | Netherlands | 1993–1998 | 48 (total) | 24/24 + 20c | 65.71 (NR) | 11–16 (range) | 2, 3, 6, 7, 8, 9 |
Choy | 2014 | Korea | 2002.1–2004.10 | 67/65 | 86/82 | 67.8 (49–80) | 9.5 | 1, 2, 3, 5, 6, 7, 8 |
Kim | 2014 | Korea | 1995.1–1996.3 | 85/85 | 80/80 | 54.3 (49–55) | 16.6 | 1, 2, 5, 7, 8 |
Henricson | 2018 | Sweden | 2003–2004 | 22/19 | 18/16 | 55 (33–59) | 10 | 2, 3, 4, 7, 9 |
Batailler | 2020 | France | 2004–2005 | 65/65 | 59/59 | 72 (50–90) | 13 | 1, 2, 3, 7, 8 |